Tarsus Pharmaceuticals, Inc. TARS Commissions and Contract Termination Costs
Commissions and Contract Termination Costs at other companies
Other financials
Where this comes from
Reported directly by Tarsus Pharmaceuticals, Inc. in its filing.
Tagged under the XBRL concept us-gaap:AccruedSalesCommissionCurrent.
The official record: Tarsus Pharmaceuticals, Inc.’s 10-Q, filed May 6, 2026, on SEC EDGAR. View the filing →
Ask your AI about Tarsus Pharmaceuticals, Inc.'s commissions and contract termination costs.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Tarsus Pharmaceuticals, Inc.'s commissions and contract termination costs?
- Tarsus Pharmaceuticals, Inc. (TARS) reported commissions and contract termination costs of $70.52M in Q1 2026.
- How has Tarsus Pharmaceuticals, Inc.'s commissions and contract termination costs changed year-over-year?
- Tarsus Pharmaceuticals, Inc.'s commissions and contract termination costs increased by 61.4% year-over-year, from $43.69M to $70.52M.
- What does commissions and contract termination costs mean?
- This represents the accrued liability for sales-related commissions and financial obligations arising from the termination of commercial contracts. It reflects short-term operational costs tied to sales performance and restructuring activities. Monitoring this helps investors assess the company's immediate cash outflow requirements related to its commercialization strategy.